← Back to Search

Behavioural Intervention

At-Home vs Clinic-Based Therapy for Advanced Cancer

Phase 2
Recruiting
Led By Roxana S. Dronca, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 24 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at the effects of giving cancer treatment at-home, instead of in a clinic, to reduce psychological/financial distress & increase treatment compliance.

Who is the study for?
This trial is for adults with advanced cancer who live within 35 miles of the clinic, can handle their current chemo well, and plan to continue it for at least 24 weeks. They need Wi-Fi at home and must be able to fill out questionnaires. People needing constant help or on other treatments (except hormone therapy), with severe illnesses, recent serious infections, or unstable heart conditions cannot join.
What is being tested?
The study compares receiving cancer treatment at home versus in a clinic setting. It aims to see if home-based care reduces stress and improves compliance with treatment plans. Participants will receive either clinical encounters or home health visits along with quality-of-life assessments through questionnaires.
What are the potential side effects?
Since patients continue their current chemotherapy regimens, side effects are not introduced by new drugs but may include typical chemo-related issues like nausea, fatigue, hair loss, increased infection risk, and potential infusion reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean patient-reported rating of Cancer Connected Access and Remote Expertise
Secondary study objectives
Emergency room visits and hospitalizations
Incidence of adverse events
Overall survival
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm B (clinic & at-home treatment)Experimental Treatment4 Interventions
Patients continue receiving their SOC chemotherapy regimen in the clinic for approximately 8 weeks in the absence of disease progression or unacceptable toxicity. Patients then begin receiving their SOC chemotherapy regimen at home as in Arm I for an approximate additional 16 weeks in the absence of disease progression or unacceptable toxicity.
Group II: Arm A (at-home treatment)Experimental Treatment3 Interventions
Patients continue receiving their SOC chemotherapy regimen at home for approximately 24 weeks in the absence of disease progression or unacceptable toxicity. This includes drug administrations, injections/infusions and routine clinical laboratory tests in the home from the HHNP, overseen by Mayo Clinic's home health program CCBW Command Center. Patients are also provided biometric devices for health monitoring vital signs, as well as a computer tablet for video visits with the Mayo Clinic care team.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,333 Previous Clinical Trials
3,059,975 Total Patients Enrolled
Roxana S. Dronca, MDPrincipal InvestigatorMayo Clinic
Roxana S. Dronca, M.D.Principal InvestigatorMayo Clinic
3 Previous Clinical Trials
139 Total Patients Enrolled

Media Library

Clinical Encounter (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05969860 — Phase 2
Myelodysplastic Syndrome Research Study Groups: Arm B (clinic & at-home treatment), Arm A (at-home treatment)
Myelodysplastic Syndrome Clinical Trial 2023: Clinical Encounter Highlights & Side Effects. Trial Name: NCT05969860 — Phase 2
Clinical Encounter (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05969860 — Phase 2
~12 spots leftby Jan 2025